1. Home
  2. EPSM vs GDTC Comparison

EPSM vs GDTC Comparison

Compare EPSM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsium Enterprise Limited Ordinary Shares

EPSM

Epsium Enterprise Limited Ordinary Shares

N/A

Current Price

$0.83

Market Cap

12.3M

Sector

N/A

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

N/A

Current Price

$0.91

Market Cap

11.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPSM
GDTC
Founded
2010
2018
Country
China
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
11.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EPSM
GDTC
Price
$0.83
$0.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 23.8K
14.9K
Earning Date
11-24-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.68
52 Week High
$10.19
$3.10

Technical Indicators

Market Signals
Indicator
EPSM
GDTC
Relative Strength Index (RSI) 36.89 52.18
Support Level $0.83 $0.73
Resistance Level $1.64 $0.96
Average True Range (ATR) 0.08 0.08
MACD -0.00 0.00
Stochastic Oscillator 32.76 90.46

Price Performance

Historical Comparison
EPSM
GDTC

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: